Wei Lin - 01 Feb 2022 Form 4 Insider Report for Erasca, Inc. (ERAS)

Role: Chief Medical Officer
Signature: /s/ Ebun S. Garner, Attorney-in-Fact
Issuer symbol: ERAS
Transactions as of: 01 Feb 2022
Transactions value $: $18,123
Form type: 4
Filing time: 03 Feb 2022, 18:54:57 UTC
Previous filing: 15 Jul 2021
Next filing: 03 Feb 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ERAS	Common Stock	Other	$18,123	+1,562	+0.5%	$11.6^*	314,062	01 Feb 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ERAS	Stock Option (Right to Buy)	Award	$0	+272,100		$0	272,100	01 Feb 2022	Common Stock	272,100	$11.54	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 1,562 shares acquired under the Erasca, Inc. employee stock purchase plan on December 15, 2021.
F2	1/48th of the shares subject to the option vest monthly following February 2, 2022, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.